Haloperidol versus risperidone on rat "early onset" vacuous chewing

Behavioural Brain Research

Volumn 149, Issue 1, 2004, Pages 9-16

  Marchese, Giorgio ^a   Bartholini, Francesco ^a   Casu, Maria Antonietta ^a   Ruiu, Stefania ^a   Casti, Paola ^a   Congeddu, Elena ^a   Tambaro, Simone ^a   Pani, Luca ^a,b  

^a Neuroscienze PharmaNess Scarl   (Italy)

^b CNR   (Italy)

Author keywords

Catalepsy; Parkinson; Purposeless chewing; Tardive dyskinesia; Tremor

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; MALE; MASTICATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0346040232     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00192-X     Document Type: Article

References (42)

1. Adams RD, Victor M. Tremors, spasms and tics. In: Principles in neurology. New York: McGraw Hill; 1995. p. 69-77.
2. Aravagiri M., Yuwiler A., Marder S.R. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy- risperidone in the brain and other tissues of rat. Psychopharmacology (Berl.). 139(4):1988;356-363.
3. Aravagiri M., Marder S.R. Brain, plasma and tissue pharmakinetics of risperidone and 9-hydroxy-risperidone after separate oral administration to rat. Psychopharmacology (Berl.). 159(4):2002;424-431.
4. Diana M., Collu M., Mura A., Gessa G.L. Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. Eur. J. Pharmacol. 211(3):1992;415-419.
5. Egan M.F., Hurd Y., Ferguson J., Bachus S.E., Hamid E.H., Hyde T.M. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl.). 127(4):1996;337-345.
6. Gil-ad I., Shtaif B., Shiloh R., Weizman A. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol. Neurobiol. 21(6):2001;705-716.
7. Gunne L.M., Growdon J., Glaeser B. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology (Berl.). 77(2):1982;134-139.
8. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl.). 120(2):1995;128-133.
9. Igarashi K., Kasuya F., Fukui M., Usuki E., Castagnoli N. Jr. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Life Sci. 57(26):1995;2439-2446.
10. Jeste D.V., Lohr J.B., Eastham J.H., Rockwell E., Caligiuri M.P. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J. Psychiatr. Res. 32(3-4):1998;201-214.
11. Jicha G., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible model of parkinsonian symptoms. J. Neurosci. 11(12):1991;3822-3829.
12. Kalkman H.O., Neumann V., Hoyer D., Tricklebank M.D. The role of alfa2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br. J. Pharmacol. 124(7):1998;1550- 1556.
13. Klawans H.L., D'amico D.J., Nausieda P.A., Weiner W.L. The specificity of neuroleptic- and methysergide-induced behavioural hypersensitivity. Psychopharmacology (Berl.). 55(1):1977;49-52.
14. Knable M.B., Heinz A., Raedler T., Weinberger D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. 75(2):1997;91-101.
15. Kusumi I., Takahashi Y., Suzuki K., Kameda K., Koyama T. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rats. J. Neural Transm. 107(3):2000;295-302.
16. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., Janssen P.A. Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 247(2):1988;661-670.
17. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry. 55(Suppl. 1):1994;5-12.
18. Liskowsky D.R., Potter L.T. Dopamine D2 receptors in the striatum and frontal cortex following chronic administration of haloperidol. Neuropharmacology. 26(5):1987;481-483.
19. Mahadik S.P., Laev H., Korenovsky A., Karpiak S.E. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol. Psychiatry. 24(2):1988;199-217.
20. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L.et al. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur. J. Neurosci. 15(7):2002;1187-1196.
21. McCoy L., Cox C., Richfield E.K. Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. Eur. J. Pharmacol. 318(1):1996;41-45.
22. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J.et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl.). 114(1):1994;9-23.
23. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 25(3):1989;390-392.
24. Mendes L.S., Collins S.P. The effects of the atypical antipsychotics, clozapine remoxipride and risperidone on the contractile characteristics of rat skeletal muscle in vitro. Pharmacol. Res. 36(6):1997;457-461.
25. Meshul C.K., Bunker G.L., Mason J.N., Allen C., Janowsky A. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem. 67(5):1996;1965-1973.
26. Naidu P.S., Kulkarni S.K. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur. J. Pharmacol. 428(1):2001;81-86.
27. Naidu P.S., Kulkarni S.K. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists. Eur. J. Pharmacol. 420(2/3):2001;113-117.
28. Ohman R., Larsson M., Nilsson I.M., Engel J., Carlsson A. Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn Schmiederbergs Arch. Pharmacol. 299(2):1977;105-114.
29. Reavill C., Kettle A., Holland V., Riley G., Blackburn T.P. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br. J. Pharmacol. 126(3):1999;572-574.
30. Ruiu S., Marchese G., Saba P.L., Satta R., Gessa G., Vaccari A.et al. In vitro evidence for the presence of [(3)H]-haloperidol uptake in rat brain. Br. J. Pharmacol. 138(1):2003;188-192.
31. Rupniak N.M., Jenner P., Marsden C.D. Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology (Berl.). 85(1):1985;71-79.
32. Rupniak N.M., Jenner P., Marsden C.D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl.). 88(4):1986;403-419.
33. Salamone J.D., Baskin P. Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Pharmacol. Biochem. Behav. 53:1996;179-183.
34. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol. 56:1998;591-611.
35. Stanford J.A., Fowler S.C. Clozapine-like motor effects of the atypical antipsychotic risperidone in rats. Neurosci. Lett. 285(3):2000;189-192.
36. Steinpreis R.E., Baskin P., Salamone J.D. Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology (Berl.). 111(1):1993;99-105.
37. Takeuchi H., Ishigooka J., Kobayashi K., Watanabe S., Miura S. Study on the suitability of a rat model for tardive dyskinesia and preventive effect of various drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22(4):1998;679-691.
38. Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description and diagnosis. Clin. Neuropharmacol. 6(Suppl. 1):1983;S9-S26.
39. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 16(1):2002;23-45.
40. Trevitt J.T., Lyons M., Aberman J., Carriero D., Finn M., Salamone J.D. Effects of clozapine thioridazine, risperidone and haloperidol on behavioural tests related to extrapyramidal motor function. Psychopharmacology (Berl.). 132(1):1997;74-81.
41. Wadenberg M.L., Kapur S., Soliman A., Jones C., Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl.). 150(4):2000;422-429.
42. Wadenberg M.L., Soliman A., Vander-Spek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 25(5):2001;633-641.